Sarcoma Cancer Surgery

Many sarcomas can be cured, particularly when they are found before spreading and are completely removed by an experienced sarcoma surgical team.

Your chance of cure depends on:

• The subtype of sarcoma
• The grade (how aggressive the cells look) – one of the most important factors
• The size and depth of the tumor
• Whether it can be removed completely with clear margins
• Whether it has spread, most often to the lungs

What the evidence shows:

• Localized soft tissue sarcoma: about 8 in 10 patients are alive five years after diagnosis.
• Localized GIST: five-year survival is over 90%, and many patients remain free of disease after surgery alone or surgery plus imatinib.
• Retroperitoneal sarcoma: complete surgery at a specialist center is associated with the best long-term control.
• Metastatic sarcoma: cure is less common, but surgery or radiation to limited lung spots, chemotherapy and targeted therapy can control the disease for long periods in some patients.

Sarcoma is a rare cancer that starts in the body's connective tissues, such as fat, muscle, tendons, nerves, blood vessels, cartilage or bone.

• Sarcomas make up only about 1% of adult cancers but a larger share of cancers in children and young adults.
• About 80% of sarcomas are soft tissue sarcomas; the rest are bone sarcomas.
• More than 70 subtypes exist, each with its own behaviour and treatment.
• Sarcomas can occur almost anywhere, but are most common in the thigh, arm, trunk and abdomen.

Soft tissue sarcomas of the limbs and trunk are usually found as a growing lump and treated with limb-sparing surgery and often radiation, while abdominal sarcomas grow silently deep in the abdomen and need complex abdominal surgery or, for GIST, targeted tablets.

Table 1. Soft tissue sarcoma vs abdominal sarcoma

The main sarcoma groups are soft tissue sarcomas, abdominal sarcomas (including retroperitoneal sarcoma and GIST) and bone sarcomas, each containing many subtypes.

Table 2. Common sarcoma subtypes at a glance

Because sarcoma is rare and complex, international guidelines recommend that patients be diagnosed and treated at a specialist sarcoma center, which is associated with better surgical results and outcomes.

• Before any biopsy or surgery: referral to a sarcoma team is recommended so the biopsy and operation are planned together.
• Unplanned removal of a sarcoma (removing a lump thought to be benign) often leaves cancer behind and may require larger re-operation.
• Expert pathology review changes or refines the diagnosis in a meaningful proportion of sarcoma cases.
• Multidisciplinary planning brings surgery, radiation and chemotherapy together in the right order.

In most cases, the cause of sarcoma is unknown, and there is no good evidence that an injury causes sarcoma, although an injury may draw attention to a lump that was already there.

• Most sarcomas occur in people with no known risk factors.
• Known risk factors include previous radiation therapy, certain inherited syndromes, chronic lymphedema and some chemical exposures (see Section 8).
• Nothing you did or did not do is likely to have caused your sarcoma.

Most patients begin sarcoma treatment within about two to six weeks of diagnosis, a timeframe generally considered appropriate for expert imaging, biopsy, pathology review and treatment planning.

• Careful planning before surgery is important, because the first operation usually offers the greatest opportunity for complete removal.
• Fast-growing tumors, bleeding GISTs or tumors pressing on nerves or organs may need quicker action.
• Your team will tell you if your situation is urgent.

Table 3. Typical timeline from diagnosis to sarcoma treatment

*Timeframes vary with your sarcoma, test availability and personal circumstances.

A second opinion is a normal, widely accepted part of sarcoma care, and given the rarity of sarcoma, an expert review of your pathology and scans is often especially valuable.

A second opinion is especially useful when:

• Your sarcoma was removed unexpectedly during surgery for a presumed benign lump
• Amputation or removal of major organs has been suggested
• The subtype is rare or the diagnosis is uncertain
• You have been offered very different treatment options

Bring these to your second-opinion appointment:

• MRI / CT images (CD or link) and reports
• Biopsy or surgical pathology report and tissue blocks / slides
• Operation notes, if you have had surgery
• Any molecular or genetic test results

Five-year survival for sarcoma depends strongly on subtype, grade and stage, ranging from over 90% for localized GIST to around 15% for soft tissue sarcomas that have spread to distant organs.

• The figures below are approximate U.S. population data (SEER) for patients diagnosed in past years.
• They combine many different subtypes and cannot predict what will happen to any one person.
• Your sarcoma team can give a more personal estimate using your subtype, grade, size and treatment.

Table 4. Approximate five-year relative survival by stage

Source: rounded approximations of U.S. SEER / American Cancer Society five-year relative survival, for general education only. Retroperitoneal sarcoma outcomes are reported mainly from specialist center series and vary widely by subtype.

Sarcoma grade describes how aggressive the cancer cells look under the microscope, and it is one of the most important predictors of whether a sarcoma is likely to spread.

Table 5. Sarcoma grade (FNCLCC system) explained

• Grade is scored using cell appearance, how fast cells are dividing and the amount of dead tumor (necrosis).
• GIST uses a different system based on size, mitotic rate and location (see below).

Sarcoma stage combines the tumor's size, grade, lymph node involvement and distant spread, and it guides treatment and prognosis.

• Soft tissue sarcoma is staged with the AJCC TNM system, with separate staging for limbs/trunk, retroperitoneum, head and neck and organs.
• Unlike most cancers, grade is built into the stage for soft tissue sarcoma.
• Lymph node spread is uncommon for most sarcomas, but more frequent in subtypes such as rhabdomyosarcoma, epithelioid, clear cell and angiosarcoma.

Table 6. Soft tissue sarcoma stages explained (limbs and trunk)

The risk that a GIST will come back after surgery is estimated from its size, its mitotic rate (how fast cells divide) and where it started, and this decides whether imatinib is recommended after surgery.

Table 7. GIST recurrence risk factors

• High-risk GISTs are usually treated with 3 years of adjuvant imatinib after surgery, which has been shown in trials to improve survival.
• The specific KIT or PDGFRA mutation also influences whether imatinib is likely to work.

Metastatic sarcoma can be treated, and some patients – particularly those with limited lung metastases or GIST – live for many years with treatment.

• Limited lung metastases: surgery (metastasectomy) or stereotactic radiation (SBRT) may give long-term control in selected patients.
• Metastatic GIST: imatinib and later-line targeted tablets can control the disease for years in many patients.
• Other subtypes: chemotherapy, subtype-specific targeted drugs and clinical trials are options.
• Supportive and palliative care alongside treatment has been shown to improve symptoms and quality of life.

Prognosis in sarcoma is shaped mainly by the subtype, grade, size, depth and stage of the tumor and whether it can be completely removed.

• Grade – high-grade tumors carry a higher risk of spread.
• Size and depth – tumors over 5 cm and deep to the muscle covering (fascia) carry higher risk.
• Surgical margins – complete removal with clear margins (R0) is associated with a lower risk of local recurrence.
• Location – retroperitoneal sarcomas are harder to remove completely than limb sarcomas.
• Subtype and molecular features – for example, KIT exon 11 mutations in GIST respond well to imatinib.
• Age and overall health – these influence which treatments are suitable.
• Specialist sarcoma care – associated with better outcomes.

The most common sign of soft tissue sarcoma is a painless lump that is growing, while abdominal sarcomas usually cause abdominal swelling, fullness, pain or bleeding from the digestive tract.

Table 8. Common symptoms by sarcoma type

Most lumps and abdominal symptoms are caused by non-cancerous conditions, but those with warning features should be assessed.

Most soft tissue lumps are benign lipomas, but a lump that is larger than 5 cm, growing, deep within the muscle, or has come back after removal should be checked with imaging before any surgery.

Table 9. Lipoma vs sarcoma: warning features

Important: A suspicious lump should be assessed with ultrasound or MRI and, if needed, a core needle biopsy at a sarcoma center before it is removed.

Abdominal and retroperitoneal sarcomas are often found late because the abdomen has room for tumors to grow very large before they press on organs or cause noticeable symptoms.

• Early symptoms such as fullness or bloating are easily mistaken for digestive problems or weight gain.
• Many are discovered on scans done for unrelated reasons.
• Even large retroperitoneal sarcomas can often still be removed by an experienced team.

See a doctor promptly for any lump that is growing, larger than 5 cm or deep, and seek emergency care for signs of internal bleeding or severe abdominal pain.

Table 10. How urgently to seek care

Sarcoma is diagnosed with imaging followed by an image-guided core needle biopsy reviewed by a specialist sarcoma pathologist, with scans of the chest to check for spread.

Table 11. Diagnostic and staging tests for sarcoma

A sarcoma biopsy should be planned by the treating sarcoma team because the needle path may need to be removed at surgery; when done correctly, the risk of spreading cancer is very low.

• Core needle biopsy (not removal of the whole lump) is the usual first step.
• The biopsy route is chosen so it can be removed with the tumor later.
• Fine-needle aspiration alone is often not enough to classify a sarcoma.
• Excisional biopsy is generally reserved for small, superficial lumps under the guidance of a sarcoma surgeon.

Table 12. What to expect on the day of a biopsy

After your biopsy:

• Follow your team's fasting and blood-thinner instructions before the procedure.
• Mild bruising or soreness for a few days is common.
• Contact your team if you notice increasing swelling, bleeding or fever.

Molecular testing identifies the gene changes that define many sarcoma subtypes, confirming the diagnosis and, in some cases, pointing to targeted treatments.

Table 13. Examples of molecular markers in sarcoma

Availability of targeted drugs varies by country.

Sarcoma biopsy results usually take about 1 to 2 weeks because specialised stains and expert review are often needed, and molecular tests can take 2 to 3 weeks.

Table 14. Typical test result turnaround times

*Turnaround times vary between laboratories.

The most suitable sarcoma treatment depends on the subtype, grade, size and location of the tumor, and is planned by a multidisciplinary sarcoma tumor board.

Table 15. Main treatments by sarcoma type

Table 16. How long does sarcoma treatment take? Typical pathways

*Durations are typical examples and vary with response, wound healing and individual plans.

Most patients with limb sarcoma do not need amputation; limb-sparing surgery, usually combined with radiation, is possible for the large majority of patients, with cancer control comparable to amputation in published studies.

• Around 9 in 10 limb sarcomas are now treated with limb-sparing surgery at specialist centers.
• Amputation may be advised when the tumor surrounds major nerves and vessels, or when a functional limb cannot be preserved.
• Reconstruction with muscle flaps, skin grafts, nerve or vessel grafts can restore function.
• When amputation is needed, modern prosthetics and rehabilitation can support an active life.

Sarcoma surgery aims to remove the whole tumor with a layer of healthy tissue around it (a wide margin), which is associated with a lower risk of local recurrence.

Table 17. Types of sarcoma surgery

Table 18. Preparing for sarcoma surgery: timeline checklist

*Always follow your own surgical team's instructions, which may differ.

Table 19. Typical hospital stay and recovery after sarcoma surgery

*Recovery varies with the extent of surgery, wound healing (especially after radiation), fitness and any complications.

Radiation therapy is commonly recommended for intermediate- and high-grade limb and trunk sarcomas to lower the risk of the tumor returning, and it is increasingly given before surgery.

Table 20. Radiation before vs after sarcoma surgery

• Each session usually takes 15–30 minutes, five days a week.
• Shorter (hypofractionated) schedules are being studied and used in some centers.
• For retroperitoneal sarcoma, pre-operative radiation may benefit selected patients, such as some with liposarcoma; it is not routine for all.

Table 21. Your radiation therapy journey step by step

*Timings vary between centers and patients.

Chemotherapy is not needed for every sarcoma; it is mainly used for high-risk localized tumors, chemotherapy-sensitive subtypes and metastatic disease.

• Commonly used for: rhabdomyosarcoma, Ewing sarcoma, synovial sarcoma, and high-grade, large, deep soft tissue sarcomas in selected patients.
• Not usually effective for: GIST (treated with targeted tablets instead) and low-grade sarcomas.
• Key drugs: doxorubicin, ifosfamide, gemcitabine, docetaxel, trabectedin, eribulin, dacarbazine.

Table 22. Common systemic treatment schedules for sarcoma

Table 23. A typical 3-week doxorubicin / ifosfamide chemotherapy cycle

*Patterns vary with the regimen and individual response.

Schedules are typical examples. Regimens and drug availability vary by country and individual circumstances.

Retroperitoneal sarcoma is primarily treated with complete surgical removal in one piece (en bloc), often with nearby organs, by a high-volume specialist sarcoma team.

• The first operation is critical – complete removal is associated with the best long-term control.
• Adjacent organs such as a kidney, part of the colon or abdominal muscle may be removed with the tumor to achieve clear margins.
• Pre-operative radiation may be considered for selected patients; trials have not shown a benefit for all.
• Chemotherapy may be used before surgery for some high-grade subtypes, or for recurrent or metastatic disease.
• Local recurrence is the main risk, especially for liposarcoma, so long-term CT follow-up is important.

GIST (gastrointestinal stromal tumor) is the most common sarcoma of the digestive tract, and most GISTs respond to imatinib, a daily targeted tablet that has substantially improved outcomes.

Table 24. Typical imatinib use in GIST

• Take imatinib with food and a large glass of water.
• If imatinib stops working, sunitinib, regorafenib and ripretinib are next-line options.
• SDH-deficient and NF1-associated GISTs usually respond less to imatinib.

Table 25. Typical monitoring while taking imatinib

*Durations and monitoring intervals are typical; your oncologist will tailor them to you.

A desmoid tumor is a locally aggressive soft tissue tumor that typically does not spread (metastasize) to other organs, and many desmoid tumors are first managed with active surveillance rather than immediate surgery.

• Some desmoid tumors stop growing or shrink on their own.
• Treatment is considered if the tumor grows, causes symptoms or threatens nearby structures.
• Options include nirogacestat or other targeted tablets, low-dose chemotherapy, radiation, cryoablation and, in selected cases, surgery.
• Desmoid tumors can be linked with familial adenomatous polyposis (FAP), so testing may be advised.

Targeted therapy is a standard treatment for GIST and several rare sarcoma subtypes, while immunotherapy benefits only selected subtypes and is often offered within clinical trials.

Table 26. Examples of targeted and immune-based therapies in sarcoma

Approvals and availability vary by country. Your oncologist will advise which options apply to your subtype.

A sarcoma tumor board is a meeting where sarcoma specialists from each relevant field review your case together to agree on a recommended treatment plan.

• Surgical oncologist (orthopaedic, general or retroperitoneal sarcoma surgeon)
• Medical oncologist
• Radiation oncologist
• Specialist sarcoma pathologist
• Musculoskeletal and abdominal radiologists
• Plastic and reconstructive surgeon
• Physiotherapist and rehabilitation specialist
• Nurse navigator, dietitian, psycho-oncologist and palliative care team

Because sarcoma is rare, clinical trials play an especially important role, and they may be a suitable option at many stages of the disease.

• Trials are carefully regulated and ethically reviewed.
• Participants generally receive at least the current standard of care.
• You can withdraw at any time.
• Ask whether trials match your subtype, especially if it is rare or has progressed.

Side effects depend on the treatment you receive; many are temporary, and most can be reduced with modern supportive care and rehabilitation.

Table 27. Common side effects and how they are managed

Many patients regain good function after limb-sparing sarcoma surgery, especially with early, structured physiotherapy, although the degree of recovery depends on the muscles, nerves and bones involved.

• Physiotherapy usually starts within days of surgery.
• Function often continues to improve for 6–12 months.
• Braces, walking aids or occupational therapy may help during recovery.
• Long-term stiffness or swelling can occur, particularly after radiation; regular stretching and compression help.

Contact your oncology team immediately, day or night, if you develop a temperature of 38°C (100.4°F) or above during chemotherapy, as this may signal a serious infection.

Table 28. When to contact your care team

Follow any specific thresholds your own team gives you. +91 88840 09955

Rehabilitation is an important part of sarcoma recovery, helping you regain strength, movement and independence after surgery and radiation.

Table 29. Typical rehabilitation milestones after limb-sparing surgery

*Milestones vary with tumor location, extent of surgery and radiation.

Some sarcoma treatments, particularly ifosfamide, doxorubicin-based chemotherapy and pelvic radiation, can affect fertility, so fertility preservation should be discussed before treatment starts.

• Women: egg or embryo freezing (usually about 2–3 weeks); ovarian tissue freezing in some cases.
• Men: sperm banking, usually possible within days.
• Pelvic radiation: may affect fertility and pregnancy; ovarian transposition may be considered.
• Imatinib: effective contraception is advised during treatment; discuss pregnancy plans with your oncologist.

Most people are encouraged to stay as active as their surgery and treatment allow and to eat a balanced, protein-rich diet to support healing.

• Follow your physiotherapist's exercise plan, especially after limb surgery.
• Aim to build up to 150 minutes of moderate activity a week once recovered, as able.
• Eat enough protein (meat, fish, eggs, dairy, legumes) to support wound healing.
• After abdominal surgery, small frequent meals may be easier.
• Check with your team before taking supplements, as some interact with imatinib or chemotherapy.

Many people continue working during parts of sarcoma treatment, often with adjusted hours, although time off is usually needed after surgery.

Table 30. Planning work around sarcoma treatment

*Individual experiences vary.

Most sarcomas have no identifiable cause, but known risk factors include previous radiation therapy, certain inherited syndromes, chronic lymphedema and some chemical exposures.

Table 31. Known sarcoma risk factors

Most sarcomas are not inherited, but a small proportion are linked to inherited syndromes, and genetic counselling is recommended when sarcoma occurs at a young age or alongside other cancers in the family.

Table 32. Inherited syndromes linked to sarcoma

• Relatives of a person with an inherited mutation generally have a 50% chance of carrying it.
• People with Li-Fraumeni syndrome may be offered surveillance such as annual whole-body MRI.

There is no screening test for sarcoma in the general population, and because most sarcomas have no known cause, prevention is generally not possible.

• Know the warning signs of a concerning lump and have it assessed early.
• People with inherited syndromes may be offered specialised surveillance programmes.
• Long-term follow-up is advised after radiation therapy for other cancers.

Recurrence risk depends mainly on the grade, size, subtype and location of the sarcoma and whether it was completely removed; most recurrences happen within the first two to three years.

• Limb and trunk sarcoma: local recurrence after expert surgery and radiation is relatively uncommon; the main risk for high-grade tumors is spread to the lungs.
• Retroperitoneal liposarcoma: local recurrence in the abdomen is the main risk and can occur many years later.
• GIST: risk depends on size, mitotic rate, location and rupture; adjuvant imatinib has been shown to reduce it for high-risk tumors.

Sarcoma follow-up involves regular examinations and scans of the original site and chest, most frequently in the first two to three years after treatment.

Table 33. Typical follow-up schedule after sarcoma treatment

• Report any new lump, swelling, persistent cough or abdominal symptoms between visits.
• Long-term follow-up also checks for late effects of treatment, such as heart effects after doxorubicin.

Recurrent or metastatic sarcoma can often still be treated, and in selected patients further surgery or radiation may provide long-term control.

• Local recurrence: further surgery, with or without radiation, is often possible.
• Lung metastases: surgical removal (metastasectomy) or SBRT may be offered when the number of spots is limited.
• Widespread disease: chemotherapy, targeted therapy or clinical trials.
• Palliative care helps control pain and other symptoms alongside active treatment.

Feeling isolated, anxious or overwhelmed after a sarcoma diagnosis is common and understandable, and emotional support is an important part of sarcoma care.

• Talk to a psycho-oncologist, counsellor or psychologist experienced in cancer care.
• Connect with sarcoma patient organisations and online communities; meeting others with the same rare cancer can reduce isolation.
• Teenagers and young adults may benefit from dedicated AYA (adolescent and young adult) support services.
• Bring a trusted person to appointments to listen and take notes.
• Tell your team about persistent low mood, anxiety or poor sleep; these can be treated.

The cost of sarcoma treatment varies widely with the type of surgery, reconstruction, radiation and drugs used, and many health insurance plans cover a large part of it.

• Personalised cost estimate from our financial counsellors
• Help with insurance pre-authorisation and cashless claims
• Guidance on government schemes and patient assistance programmes for targeted drugs such as imatinib
• [Add your hospital's insurance partners and financial assistance details here.]

Table 34. Cost estimate overview (to be completed by hospital)

Preparing a list of questions before your first appointment helps you understand your sarcoma diagnosis and take an active part in treatment decisions.

• What subtype of sarcoma do I have, and has it been confirmed by a specialist sarcoma pathologist?
• What is the grade and stage, and has it spread?
• Have molecular tests been done on my tumor?
• Can the tumor be removed completely? Will I keep my limb or organs?
• Do I need radiation, and should it be before or after surgery?
• Will chemotherapy or targeted therapy help my subtype?
• What is the goal of treatment: cure, long-term control or symptom relief?
• What side effects and rehabilitation should I expect?
• Will treatment affect my fertility?
• Should I or my family have genetic testing?
• Am I eligible for any clinical trials?
• Who do I contact with questions or in an emergency?

Table 35. What to bring to your first appointment